Close
Top Videos
Top Searches
Moods
Black Lives Matter
Chill
Christmas
Commute
Energy boosters
Feel-Good
Focus
Party
Pride
Romance
Sad
Sleep
Workout
Genres
African
Arabic
Blues
Bollywood & Indian
Christian & Gospel
Classical
Country and Americana
Dance and electronic
Decades
Family
Folk and acoustic
Hip-hop
Indie and alternative
J-Pop
Jazz
K-Pop
Latin
Mandopop & Cantopop
Metal
Pop
R&B and Soul
Reggae and Caribbean
Rock
Soundtracks and musicals
Gene therapy for SCD: unanswered questions
01:10
|
Download MP3
Related Videos
5:11
iStopMM: the psychological effects of MGUS screening and changes to clinical presentation of myeloma
3:08
Welcome to the Video Journal of Hematology & Hematological Oncology 🎥🩸
1:31
Frontline treatment for CLL: the changing paradigm
2:08
The VENICE-1 trial: venetoclax monotherapy in R/R CLL
2:01
The evolution of BCL2 inhibition in CLL
1:26
Prognostic and predictive biomarkers in CLL and their potential in guiding treatment decisions
3:02
The role of asparaginase in the treatment of ALL
1:51
BTK degraders for CLL: agents that are currently in development
0:44
Early detection and interception across hematological cancers
3:56
Autoimmune cytopenias in CLL and the impact of targeted therapies
2:10
A study investigating the incidence of treatment-emergent autoimmune cytopenias in CLL
2:21
Targeting B-cell receptor signaling with BTK degraders to treat CLL
1:13
The main treatment goals in LR-MDS and how these differ from HR-MDS
0:47
Advice for physicians when managing bispecific antibody treatment for patients with myeloma
1:13
Using integrative multiomics to explain myeloma progression and evolution of refractory disease
1:17
Frailty-adapted therapy in myeloma: session takeaways
0:51
Predicting which patients with SMM will progress to multiple myeloma
2:13
Personalizing the timing of SCT in patients with myelofibrosis
2:00
Areas of research currently being explored for ultra-high-risk multiple myeloma
3:11
Defining and identifying ultra-high-risk multiple myeloma
5:11 3:08 1:31 2:08 2:01 1:26 3:02 1:51 0:44 3:56 2:10 2:21 1:13 0:47 1:13 1:17 0:51 2:13 2:00 3:11
